Resources
Inside Precision Medicine Published Online: August 18, 2022 Read the Full Article >> Artificial intelligence (AI) has promised major breakthroughs in clinical development success. While the hype has sometimes seemed overblown, AI is starting to deliver on those promises through real-world impact. AI is not a silver bullet for all challenges, but in specific applications,[…]
Read the Press Release >> BOSTON, June 23, 2022 /PRNewswire/ — OM1, a leading real-world data, outcomes and technology company with a focus on chronic diseases, today announced the publication of their validation of a machine learning approach to estimate expanded disability status scale scores for multiple sclerosis in the Multiple Sclerosis Journal by[…]
First Published June 22, 2022 – Multiple Sclerosis Journal Assessment of multiple sclerosis (MS) disease activity is critical for understanding treatment effectiveness, informing treatment decisions, and monitoring disease progression. Magnetic resonance imaging (MRI) findings, clinician-administered assessments, and patient questionnaires are used to measure disease activity and track changes over time. The Expanded Disability Status Scale[…]
BioPharma Dive Online Read the Full Article>> Health inequities around the world produce disparities of a shocking magnitude. For example, life expectancy from birth ranges from approximately 55 to 85 years old depending on the country in which a child is born. Linked with degrees of social disadvantage, these same profound differences can be seen[…]
Pharmaceutical Executive Online Read the Full Article >> An estimated 64 million people suffer from heart failure (HF) globally. Americans have a 20% lifetime risk of developing HF. Although recent progress in the development of new treatments has led to a modest decrease in morbidity and mortality, mortality for heart failure patients remains unacceptably high[…]
